MedTrace Logo

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

NCT07678931 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-07-01

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.

Conditions

  • Seasonal Allergic Rhinitis (SAR)

Interventions

BIOLOGICAL

Stapokibart

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Chengdu Kangnuoxing Biopharma,Inc.

    lead INDUSTRY

Principal Investigators

  • Luo Zhang · Beijing Tongren Hospital Affiliated to Capital Medical University

  • Chengshuo Wang · Beijing Tongren Hospital Affiliated to Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07678931 on ClinicalTrials.gov